A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas.
Pirosa M, Zhang L, Hitz F, Novak U, Hess D, Terrot T, Pascale M, Mazzucchelli L, Bertoni F, Cavalli F, Zucca E, Stathis A. A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas. Leuk Lymphoma 2021; 63:117-123.
19.08.2021
A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas.
19.08.2021
Leuk Lymphoma 2021; 63:117-123
Pirosa Maria C, Zhang Lu, Hitz Felicitas, Novak Urban, Hess Dagmar, Terrot Tatiana, Pascale Mariarosa, Mazzucchelli Luca, Bertoni Francesco, Cavalli Franco, Zucca Emanuele, Stathis Anastasios
Weiter
